Telix Pharmaceuticals announced an agreement to acquire ITM Isotope, a German radiopharmaceutical company, for $1.65 billion. The acquisition is intended to expand Telix's radiopharmaceutical capabilities and product portfolio.
The acquisition represents a significant expansion of Telix's radiopharmaceutical business, a growing sector in targeted cancer diagnostics and treatment.
No published comments yet.
The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.
Recent SEC-reported share and derivative transactions in Telix Pharmaceuticals Ltd.
1 discretionary purchases · 0 discretionary sales
Confidence: Low
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| Group Chief Financial OfficerSmith Darren Charlton | Informative buy | Ordinary SharesOpen-market or private transaction (P) | 2,071 | $9.656 | $19,998 | Sep 7, 2026 |
| MD & Group CEOBehrenbruch Christian | Informative buy | Ordinary SharesOpen-market or private transaction (P) | 33,435 | $14.87 | $497,178 | Apr 29, 2026 |
| MD & Group CEOBehrenbruch Christian | Informative buy | Ordinary SharesOpen-market or private transaction (P) | 34,500 | $14.48 | $499,560 | Apr 28, 2026 |
| Group Chief Financial OfficerSmith Darren Charlton | Non-informative buy | Ordinary SharesExercise or conversion; not an open-market trade (M) | 1,111 | — | — | Mar 29, 2026 |
As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 0.94%
Open short positions reported twice monthly; this is not daily short-sale volume.
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Fmr Llc | Sell | -3,551 (-0.629%) | 561,206 | $7,066 | 6/30/2026 |
| Lazard Asset Management Llc | Sell | -5,710 (-1.97%) | 284,207 | $3,578 | 6/30/2026 |
| Portland Investment Counsel Inc. | Unchanged | 0 (0%) | 266,200 | $3,351 | 6/30/2026 |
| Private Advisor Group, Llc | Buy | 22,835 (13.092%) | 197,250 | $2,483 | 6/30/2026 |
| Marshall Wace, Llp | Buy | 189,188 (New) | 189,188 | $2,382 | 6/30/2026 |
| Morgan Stanley | Buy | 49,538 (42.544%) | 165,978 | $2,090 | 6/30/2026 |
| Integrated Wealth Concepts Llc | Unchanged | 0 (0%) | 164,397 | $2,070 | 6/30/2026 |
| Hennion & Walsh Asset Management, Inc. | Buy | 150,138 (New) | 150,138 | $1,890 | 6/30/2026 |
| Ubs Group Ag | Buy | 102,398 (317.022%) | 134,698 | $1,696 | 6/30/2026 |
| Blair William & Co/Il | Buy | 122,985 (New) | 122,985 | $1,548 | 6/30/2026 |
| Raiffeisen Bank International Ag | Sell | -15,000 (-11.538%) | 115,000 | $1,448 | 6/30/2026 |
| Quadrature Capital Ltd | Buy | 102,425 (New) | 102,425 | $1,290 | 6/30/2026 |
Source: Nasdaq
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Aug 31, 2026 | 264,943 | 147,160 | +8.18% | 1.80 |
| Aug 14, 2026 | 244,900 | 106,104 | -11.80% | 2.31 |
| Jul 31, 2026 | 277,664 | 108,323 | -6.55% | 2.56 |
| Jul 15, 2026 | 297,140 | 165,030 | +82.71% | 1.80 |
| Jun 30, 2026 | 162,625 | 213,105 | -16.16% | 1.00 |
| Jun 15, 2026 | 193,969 | 235,552 | -22.81% | 1.00 |
| May 29, 2026 | 251,276 | 116,627 | +15.64% | 2.15 |
| May 15, 2026 | 217,298 | 116,382 | — | 1.87 |
Source: Nasdaq
